Phase 2 Intermin Data
Amp Volatility Score
Catalyst Info & Data Links
TITLE: AFM13-202 (REDIRECT) for CD-30 positive peripheral T cell lymphoma (PTCL) Phase 2 interim Data
Clinical Trial (NCT04101331) : Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)
WHAT IS THE NEXT CATALYST EVENT?
Phase 2 Interim Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION
AFM13 is a first-in-class tetravalent, bispecific innate cell engager that specifically binds to CD30 on tumor cells and to CD16A on NK cells and macrophages. AFM13 is being developed in peripheral T cell lymphoma (pTCL) and in other CD30-positive lymphomas. AFM13 has shown a favorable safety profile and signs of therapeutic efficacy as a monotherapy in CD30-positive non-Hodgkin lymphoma with cutaneous manifestation. In addition, data from a combination study of AFM13 with Merck’s anti-PD-1 antibody Keytruda® (pembrolizumab) in Hodgkin lymphoma (HL) supports proof of principle for the combination of NK cell engagement with checkpoint inhibition. AFM13 has been granted orphan drug designation by the U.S. Food and Drug Administration for HL.
Updated by MV
AFM13, REDIRECT, AFMD, cancer, peripheral T Cell Lymphoma (PTCL), CD30 positive
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post